泌尿系统恶性肿瘤的个体化新抗原疫苗。

IF 28.5 1区医学 Q1 ONCOLOGY

Nature cancer Pub Date : 2025-05-09 DOI:10.1038/s43018-025-00944-z

Behzad Jazayeri, Roger Li

引用次数: 0

摘要

个体化新抗原疫苗利用突变驱动的新抗原诱导肿瘤特异性免疫反应。这种策略现在被证明是可行和安全的，有初步证据表明对尿路上皮癌或肾细胞癌患者有效和具有免疫原性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Personalized neoantigen vaccines in urologic malignancies

查看原文本刊更多论文

Personalized neoantigen vaccines in urologic malignancies

Personalized neoantigen vaccines utilize mutation-driven neoantigens to induce tumor-specific immune responses. This strategy is now shown to be feasible and safe, with preliminary evidence of efficacy and immunogenicity in patients with urothelial cancer or renal-cell carcinoma.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature cancer Medicine-Oncology

CiteScore

31.10

自引率

1.80%

发文量

129

期刊介绍： Cancer is a devastating disease responsible for millions of deaths worldwide. However, many of these deaths could be prevented with improved prevention and treatment strategies. To achieve this, it is crucial to focus on accurate diagnosis, effective treatment methods, and understanding the socioeconomic factors that influence cancer rates. Nature Cancer aims to serve as a unique platform for sharing the latest advancements in cancer research across various scientific fields, encompassing life sciences, physical sciences, applied sciences, and social sciences. The journal is particularly interested in fundamental research that enhances our understanding of tumor development and progression, as well as research that translates this knowledge into clinical applications through innovative diagnostic and therapeutic approaches. Additionally, Nature Cancer welcomes clinical studies that inform cancer diagnosis, treatment, and prevention, along with contributions exploring the societal impact of cancer on a global scale. In addition to publishing original research, Nature Cancer will feature Comments, Reviews, News & Views, Features, and Correspondence that hold significant value for the diverse field of cancer research.